COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy and Nivolumab in men with mCRPC
This was a multi-center, single-arm, open-label phase 2 trial of men with mCRPC who received testosterone cypionate 400mg intramuscular (BAT) every 28 days and nivolumab 480mg IV every 28 days, during which time LHRH agonist treatment was continued.
This was a multi-center, single-arm, open-label phase 2 trial of men with mCRPC who received testosterone cypionate 400mg intramuscular (BAT) every 28 days and nivolumab 480mg IV every 28 days, during which time LHRH agonist treatment was continued.